Intrapleural Measles Virus Therapy in Treating Patients with Malignant Pleural Mesothelioma

Inclusion Criteria

• PRE-REGISTRATION:
• Diagnosis of MPM, confined to single pleural cavity, with histologic confirmation of the primary tumor
• Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesothelioma
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
• Ability to provide informed consent
• Willingness to return to Mayo Clinic Rochester for follow up
• Life expectancy >= 12 weeks (in the opinion of the enrolling investigator)
• Willingness to provide the biologic specimens
• Dose Escalation cohort only: Willingness to participate in the SPECT/CT imaging as required by the protocol
• Presence of a pleural effusion with the ability to safely place an intrapleural catheter or have pre-existing intrapleural catheter
• Absolute neutrophil count (ANC) >= 1500/uL
• Platelet count >= 100,000/uL
• Total bilirubin =< 1.5 x upper limit of institutional normal
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 x upper limit of institutional normal
• Serum creatinine =< 1.5 x upper limit of institutional normal
• Hemoglobin >= 9.0 g/dL
• Must be willing to implement contraception throughout study and for the 4 weeks following last viral administration
• REGISTRATION:
• Anti-measles immunity as demonstrated by serum immunoglobulin (Ig)G anti-measles antibody levels of >= 1.1 EU/ml as determined by BioPlex Measles IgG multiplex flow immunoassay
• Hepatitis B and C negative
• Human immunodeficiency virus (HIV) negative
• Cluster of differentiation 4 (CD4) count >= 200/uL
• CT imaging review submission to confirm unilateral pleural involvement; this review for CT imaging is mandatory prior to registration to confirm eligibility; it should be initiated as soon as possible after pre-registration
• Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only

Exclusion Criteria

• PRE-REGISTRATION
• Uncontrolled intercurrent illness including, but not limited to: * Active infection =< 5 days prior to pre-registration * Psychiatric illness/social situations that would limit compliance with study requirements * Symptomatic congestive heart failure New York Heart Association classification III or IV * Symptomatic coronary artery disease (CAD) * Symptoms of CAD on systems review * Cardiac arrhythmias
• Any of the following therapies prior to pre-registration: * Chemotherapy =< 4 weeks * Immunotherapy =< 4 weeks * Biologic therapy =< 4 weeks; Note exception: prior viral and/or gene therapy are exclusion criteria * Radiotherapy =< 4 weeks
• Failure to fully recover from acute, reversible effects of prior anti-cancer therapy regardless of interval since last treatment; NOTE: patients must have fully recovered from all acute, reversible toxicities (defined as Common Terminology Criteria for Adverse Events [CTCAE] 4.0 =< grade 1) associated with previous treatment
• Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception
• Any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) or any other treatment specifically for treating the current malignancy
• Immunocompromised patients, including patients known to be HIV positive
• History of organ transplantation
• Known hepatitis B or C
• Treatment with oral/systemic corticosteroids; NOTE: with the exception of topical or inhaled steroids
• Exposure to household contacts =< 15 months old or household contact with a person with known immunodeficiency
• Allergy to measles vaccine or history of severe reaction to prior measles vaccination
• Dose Escalation cohort only: Allergy to iodine; NOTE: this does not include reactions to intravenous contrast materials
• History of tuberculosis or purified protein derivative (PPD) skin test positivity
• Inability or unwillingness to have pleural catheter placed
• Requiring ongoing blood product support at time of pre-registration